Free Trial

Amedisys (AMED) Competitors

Amedisys logo
$93.56 -0.03 (-0.03%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$93.54 -0.02 (-0.02%)
As of 07:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, OPCH, and BTSG

Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Laboratory Co. of America (LH), Quest Diagnostics (DGX), Option Care Health (OPCH), and BrightSpring Health Services (BTSG).

Amedisys vs.

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations.

DaVita has a net margin of 7.31% compared to Amedisys' net margin of 3.57%. DaVita's return on equity of 115.48% beat Amedisys' return on equity.

Company Net Margins Return on Equity Return on Assets
Amedisys3.57% 12.20% 6.74%
DaVita 7.31%115.48%4.94%

Amedisys has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$2.37B1.29-$9.75M$2.7134.52
DaVita$12.97B0.81$936.34M$10.0913.73

DaVita received 2 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 61.10% of users gave DaVita an outperform vote while only 58.63% of users gave Amedisys an outperform vote.

CompanyUnderperformOutperform
AmedisysOutperform Votes
496
58.63%
Underperform Votes
350
41.37%
DaVitaOutperform Votes
498
61.10%
Underperform Votes
317
38.90%

Amedisys presently has a consensus price target of $100.75, indicating a potential upside of 7.68%. DaVita has a consensus price target of $164.50, indicating a potential upside of 18.73%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Amedisys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedisys
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
DaVita
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, DaVita had 18 more articles in the media than Amedisys. MarketBeat recorded 24 mentions for DaVita and 6 mentions for Amedisys. Amedisys' average media sentiment score of 1.67 beat DaVita's score of 1.12 indicating that Amedisys is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amedisys
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
DaVita
15 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by insiders. Comparatively, 2.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

DaVita beats Amedisys on 10 of the 17 factors compared between the two stocks.

Get Amedisys News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMED vs. The Competition

MetricAmedisysHome health care services IndustryMedical SectorNASDAQ Exchange
Market Cap$3.07B$3.16B$5.33B$8.39B
Dividend YieldN/A0.34%5.21%4.11%
P/E Ratio37.1329.4826.7119.71
Price / Sales1.291.13386.47120.65
Price / Cash14.8017.2938.2534.62
Price / Book2.733.596.774.50
Net Income-$9.75M-$57.02M$3.23B$248.22M
7 Day Performance-1.12%-3.66%0.48%-0.78%
1 Month Performance-0.02%15.03%9.10%11.53%
1 Year Performance-2.74%26.93%18.56%8.99%

Amedisys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMED
Amedisys
2.6801 of 5 stars
$93.56
0.0%
$100.75
+7.7%
-3.3%$3.07B$2.37B37.1320,000Positive News
DVA
DaVita
3.9979 of 5 stars
$144.29
+0.4%
$166.33
+15.3%
+2.8%$11.09B$12.82B13.4370,000Positive News
CHE
Chemed
4.7068 of 5 stars
$569.50
-0.1%
$674.00
+18.3%
+0.6%$8.33B$2.49B28.7814,200Positive News
Dividend Announcement
CRVL
CorVel
1.0099 of 5 stars
$114.08
+1.4%
N/A+22.7%$5.86B$871.31M67.114,230News Coverage
Positive News
Earnings Report
Upcoming Earnings
MD
Pediatrix Medical Group
1.3332 of 5 stars
$14.34
-1.3%
$16.67
+16.2%
+85.6%$1.23B$1.98B-11.957,850Positive News
AMN
AMN Healthcare Services
4.5295 of 5 stars
$22.67
+3.0%
$38.67
+70.6%
-62.0%$865.75M$2.85B-5.894,230Positive News
CCRN
Cross Country Healthcare
3.8995 of 5 stars
$13.92
-0.6%
$18.41
+32.2%
-7.1%$456.34M$1.26B-278.342,700Positive News
LH
Laboratory Co. of America
4.7403 of 5 stars
$250.89
+2.1%
$270.62
+7.9%
+20.2%$21.00B$13.18B28.4575,500Positive News
DGX
Quest Diagnostics
4.8424 of 5 stars
$175.93
-0.6%
$185.73
+5.6%
+19.5%$19.64B$10.16B22.8849,000News Coverage
Positive News
Analyst Revision
OPCH
Option Care Health
4.2133 of 5 stars
$31.86
+0.1%
$35.50
+11.4%
+10.3%$5.22B$5.19B26.775,600Positive News
BTSG
BrightSpring Health Services
1.6286 of 5 stars
$22.35
-2.1%
$22.89
+2.4%
+99.7%$3.89B$11.86B-85.9635,000Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:AMED) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners